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StressFibromyalgia is a diffuse chronic pain condition that occurs predominantly inwomen andmay be under-reported
in men. Symptoms include a loss of feeling of well-being and generalized widespread ﬂu-like muscle aches and
pain that fail to resolve due to central sensitization of nociceptive neurons. It has commonalities with amyriad of
other chronic pain conditions which include PTSD, “Gulf War Syndrome”, and various stress-induced conditions
caused, for example, by viral infection, emotional or physical stress, trauma, combat, accident or surgery. It is not
understood why some individuals are susceptible to this condition and others are not. White et al., elsewhere in
this issue, present a clinical feasibility study designed to test the hypothesis that 1) low or deﬁcient testosterone
serum levels are linked to a high risk for an inﬂamed nociceptive nervous system and resultant chronic pain
states, and 2) a testosterone transdermal gel applied once a day byﬁbromyalgia patients can be an effective ther-
apeutic against chronic pain. Here, a short proﬁle of ﬁbromyalgia is provided along with a brief summary of best
practices currently recommended by clinical specialists. The link between testosterone and pain is then
discussed, with an overview of scientiﬁc studies that lay the foundation for testosterone as a possible important
additional therapeutic that has the potential to be safely administered and effective but also avoid the adverse
effects of other therapeutics. Finally, novel mechanisms by which testosterone therapy is likely to down-
modulate pain signaling are proposed.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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1.1. Fibromyalgia is a disorder deﬁned by “central sensitization”.
Fibromyalgia is a diffuse non-focal chronic pain condition that
occurs in 2–4% of the population, while the incidence among women
aged 50–80 is even higher at 6–7% [1]. Fibromyalgia is thought to be
stressor-induced, for example by a viral infection, physical or emotional
stress, a traumatic accident, combat or surgery. Parallel phenomena are
the chronic pain and fatigue found in syndromes such as Post Traumatic
Stress Disorder (PTSD), “Gulf War Syndrome” and “Shell Shock”. In this
context, an allostatic load (stress) leads to a state of “distress” vs the
healthy response of “eustress” [2,3]. A “wind-up” phenomenon in which
repetitive activation of nociceptive nerves or C-ﬁbers leads to augmented
responseswith additional input of nociceptive signals, associated early on
with allodynia andhyperalgesia inﬁbromyalgia syndrome, results in neu-
ronal plasticity and an altered pathologic state [4–6].
Specialists link this condition to a dysfunctional state of the nocicep-
tive nervous system known as “central sensitization” and some investi-
gators now use that term to describe ﬁbromyalgia [7]. Normally, the
nociceptive nervous system relays painful stimuli via peripheral sensory
nerves to the CNS, and in time that pain is ultimately resolved by the
down-modulation of both ascending and descending nociceptive sig-
naling circuitry, allowing return to a healthy pain-free resting state.
Some patients, however, fail to return to a pain-free state, even after
the precipitating insult or stressor appears to have been resolved, caus-
ing clinicians to puzzle over why some patients get better and others
don't. One possible explanation that is explored here, and tested in a
companion paper in this issue, is a deﬁciency of testosterone in some in-
dividuals and not others.
The hallmarks of most peripheral inﬂammatory pain conditions are
highWBC counts or local swelling, redness and soreness. In contrast, ﬁ-
bromyalgia patients have normal WBC counts, a normal erythrocyte
sedimentation rate (which is usually elevated for inﬂammatory pain
states in the clinic) and a lack of localized swelling or inﬂamed joints.
Important early ﬁndings included the high levels of Substance P found
in the cerebrospinal ﬂuid of ﬁbromyalgia patients [8,9], and the use of
fMRI to evaluate altered patterns of cerebral activation and abnormally
low pain thresholds when applying painful pressure to ﬁbromyalgia
patients compared with controls [10]. Substance P is of interest since
it can amplify wind-up phenomena in chronic pain states and it has a
pro-inﬂammatory effect on neutrophils, macrophages and lymphocytes
[11]. Pathological features of chronic pain states within the nervous
system include activated microglia within the spinal cord and activated
sensory neuron-afﬁliatedmacrophages, as exempliﬁed by cancer patients
with chemotherapy-induced peripheral neuropathy [12]. Fibromyalgia is
therefore best described as an inﬂamed nociceptive nervous system, dis-
tinctly different from various inﬂammatory states with highWBC counts
in peripheral tissues.1.2. Treatment guidelines for ﬁbromyalgia patients
Current treatment guidelines for patients with ﬁbromyalgia
include patient education, exercise, cognitive behavioral therapy,
CNS neurostimulatory therapies and pharmacologic therapies, which
include NSAIDS, serotonin norepinephrine reuptake inhibitors (SNRI),
selective serotonin reuptake inhibitors (SSRI), tricyclic compounds,
gabapentinoids, and the opioid antagonist naltrexone [7,13]. It is general-
ly recognized, however, that these therapeutics can have suboptimal efﬁ-
cacy and/or adverse effects. NSAIDS are problematic when used for
chronic conditions due to a signiﬁcant risk for GI tract irritation; the side
effects for anti-depressants such as SSRIs can be numerous and include
risk of sexual dysfunction; and the gabapentinoids, including Pregabalin,
have common side effects such as drowsiness, dizziness, fatigue, changes
in libido and, for men, erectile dysfunction.Opioids are sometimes prescribed but are now considered to be less
effective for treating chronic pain than previously thought and their
risk–beneﬁt proﬁle is poor due to serious adverse effects such as addic-
tion, tolerance and opioid-induced hyperalgesia [7,14]. Opioids are also
known to induce androgen deﬁciency (opioid-induced androgen deﬁ-
ciency, OPIAD) causing loss of libido and sexuality. Testosterone therapy
in the presence of opioids has been used for treating the testosterone
deﬁciency component in these patients, in combination with more
aggressive opioid treatment for treating the pain component [15–18].
Testosterone therapy in the absence of exogenous opioids, however,
has not been used for treating chronic pain in humans.
For the preliminary study described byWhite et al., elsewhere in this
issue, the hypothesiswas tested that testosterone therapy could be used
to treat the chronic pain and fatigue of ﬁbromyalgia patients without
the well known side effects of currently prescribed pharmacologic
agents. The rationale for using testosterone therapy resides in the com-
bination of knowledge from diverse ﬁelds including reproductive endo-
crinology related to the gonadal steroid hormones, nociception, neuro-
endocrinology and reproductive immunology.
1.3. Preclinical and human studies causally link testosterone and pain
1.3.1. Gonadal steroid hormones and sexual dimorphisms
The function of androgens and their receptors, along with the
knowledge that androgen receptors have been found and mapped out
in the rodent brain, is associated with sexual differentiation during
fetal development and reproductive behavior [19,20]. The relationship
between testosterone and pain threshold has been investigated in ani-
mals [21–24], but the prevailing view has been that sex steroid
hormones are involved early in the life of an animal to organize pain cir-
cuitry differentially by gender, resulting in the sexual dimorphisms ob-
served for pain processing in adult males vs females [25]. No one has
previously extended this concept further to consider whether exoge-
nous sex steroid hormones, and testosterone in particular, can be used
therapeutically to dampen pain in adult humans with low serum levels
of testosterone and an inﬂamed nociceptive nervous system, even
though serum free testosterone concentrations have been shown to be
signiﬁcantly decreased in premenopausal ﬁbromyalgia patients relative
to healthy volunteers [26].
1.3.2. Initial evidence of a role for testosterone in nociception
The discovery of aromatase-positive cells in the dorsal horn of the
quail spinal cord [27] points to a role for testosterone in the regulation
of pain threshold in adults. It is the dorsal horn where initial processing
of pain sensation occurs (sensory neurons from the periphery synapse
with CNS nociceptive relay neurons) and where transmission of noci-
ceptive information to the thalamus and cerebral cortex via the antero-
lateral spinothalamic tract originates. Consistent with this, aromatase
knockout (ArKO) mice unable to convert testosterone to 17β-estradiol
have been shown to display increased nociceptive behaviors (decreased
pain thresholds) upon challenge [28]. Thus, any testosterone/
aromatase-dependent estrogen-mediated transcription of opiates,
which has been shown to occur in the spinal and medullary dorsal
horn [29–32], will not take place.
1.3.3. The inverse relationship between gonadal steroid hormones and
inﬂammation
The concept that there is an inverse correlation between gonadal
steroid hormones (estrogens, progestins and androgens) and inﬂam-
mation, however, is well documented but underappreciated. First, at
puberty, gonadal steroid hormone serum levels surgewhen the thymus
correspondingly undergoes “involution”, in which there is decreased
thymic cellularity, decreased thymic cell development, and decreased
thymic cell output to the periphery. Second, during pregnancy, an
acute surge in gonadal steroid hormone serum levels results in further
thymic involution, greatly decreased numbers of peripheral thymocytes
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Fig. 1.Hypothesized signaling pathway for testosterone in relation to nociception in the CNS.
A. In normal individuals, a painful/stressful stimulus up-regulates Substance P in the nocicep-
tive relay neurons and serotonin levels drop, consistent with a loss of feeling of well-being
[64]. Substance P has been found to stimulate aromatase [58], which would catalyze the
conversion of testosterone to estradiol within the CNS, with subsequent upregulation of
opiates and consequent dampening of pain. B. In ﬁbromyalgia patients, deﬁcient levels of
testosterone are predicted to result in a “frustrated” cycle (due to lack of substrate) in
which conversion of testosterone to estradiol is inadequate for induction of opiate-mediated
dampening of nociceptive signals, resulting in abnormal chronic, diffuse, widespread
pain. Estradiol, refers to 17-beta estradiol. See text for details and other hypothesized testos-
terone-based mechanisms.
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quently increased susceptibility to infection (rubella or rubeola viruses
for example) which is well recognized in the clinic to be harmful to
the fetus or abortogenic. Third, gonadectomy in animal models results
in a reversal of thymic involution, restoration of thymic cellularity and
thymic output and an increased T cell repertoire [33]. Finally, rescue of
gonadectomy with exogenous hormones, reverses these events [34].
1.3.4. The inverse relationship between testosterone and hyperalgesia
Gonadectomy of male and female rats has been shown to result
in increased pain responses (lower thresholds) to the formalin test,
concomitant with decreased testosterone plasma levels; conversely,
treatment of gonadectomized animals with testosterone resulted in de-
creased pain responses concomitant with increased testosterone plas-
ma levels [22,23,35]. So, although testosterone and the sex steroid
hormones in general have organizational effects on the CNS early in
life [36], substantial evidence is consistent with the concept that testos-
terone can also modulate pain therapeutically in adult rodents, both
male and female.
Animal studies have also shown that the state of pregnancy corre-
lates with signiﬁcantly increased pain thresholds mediated by endoge-
nous opioid hormone production [37], at a time when testosterone
levels are normally unusually high [38]. Data supporting a role for an-
drogens and estrogens in up-regulating opiate production in the spinal
dorsal horn nociceptive relay cells [21,27] provide onemechanistic basis
for testosterone involvement in pain perception (Fig. 1, discussed in
more detail below). Other sites within the nociceptive system appear
to be important as well: androgen and estrogen receptors have also
been localized to midbrain PAG neurons projecting to the medullary
RVM in male and female rats [39–41], as well as male primates [42];
and the male rat locus coeruleus, an important site in the pons for
brain synthesis of noradrenaline and involved in descending pain inhi-
bition pathways, has also been found to be androgen receptor positive
[39]. Neonatal castration ofmale rat pupswas found to result in reduced
analgesia in adults whenmorphinewas injected into the PAG, and neo-
natal androgenization of female rat pups treated with testosterone pro-
pionate resulted in enhanced PAGmorphine analgesia as adults [43,44].
1.3.5. Human brain imaging studies support a causal link between testos-
terone and pain
Consistent with the pre-clinical data above, brain imaging data sup-
port a role for androgens within the RVM in the brainstem of women
[45]: In a group of contraceptive pill users with signiﬁcantly reduced
serum testosterone levels, fMRI activity in the RVMwas signiﬁcantly re-
duced and an overall altered central response to noxious stimulation
was observed concomitant with decreased pain threshold upon heat
stimulus challenge, whereas no correlation was found with reduced
serum estrogen levels. Other retrospective studies have shown the inci-
dence of pain was decreased in female-to-male transgender individuals
treated with androgen, and increased in male-to-female transgender
individuals whose serum androgen levels were pharmacologically
lowered [46]. These studies support a role for testosterone in dampen-
ing pain and raising the pain threshold.
1.4. Inhibition vs facilitation of nociception
Investigators are gaining a fuller understanding of nociceptive pain
(relevant to ﬁbromyalgia patients) and the ascending/descending facil-
itation vs inhibition pathways between the midbrain periaqueductal
gray neurons (PAG), the rostral ventromedial medulla (RVM) within
the brain stem and the dorsal horn of the spinal cord that result in
hyperalgesia vs dampening of pain and return to homeostasis [47–52].
Input into this system from the hypothalamus, amygdala, other neocor-
tical areas as well as the dorsal horn provides nociceptive “context” that
informs pain pathways. Opioid microinjection or electrical stimulation
of the enkephalin rich and androgen receptor-positive PAG neuronsexcites neurons of the RVM, some containing serotonin, which project
to and inhibit the ﬁring of spinal pain-transmission neurons [53]. On-
cells, off-cells and neutral cells within the RVM help regulate this com-
plex process [54].1.4.1. Stress and the ability of testosterone to facilitate endocrine, nociceptive
and immunologic cross-talk
Behavioral factors, stressors/threatening situations or behavioral
needs can have anti-nociceptive effects that block otherwise nocicep-
tive input, allowing the animal or individual to navigate between threat
and safety/survival, including eating and reproduction [47]. In this con-
text, we hypothesize the sex steroid hormone testosterone is well posi-
tioned to facilitate neuroendocrine “cross-talk” between reproductive,
immunologic, HPA stress endocrine response andnociceptive relay neu-
ron systems. Chronic stress or pain causes signiﬁcant decreases in repro-
ductive hormone production from both the adrenal gland (HPA axis)
and ovary (HPO axis) [55], as observed in men undergoing military en-
durance/stress training [56] and in rats in response to formalin-induced
tonic pain [57]. Exhaustion of testosterone responses to stressors then
results in the hallmark symptoms for both testosterone deﬁciency and
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tion, and a low threshold for pain as hypothesized below.
1.5. Novel androgen deﬁciency hypothesis of chronic pain and central
sensitization
Clinical data now support the hypothesis that testosterone therapy
can decrease pain responses (White et al., elsewhere in this issue).
Testosterone is more available (vs estrogen) to cross the blood brain
barrier (BBB) free of sex hormone binding globulin (SHBG; it is testos-
terone that is unbound to SHBG that is bioactive), and was predicted
to be the sex steroid hormone that is important for modulating the
sensation of pain in the dorsal horn and other key sites within the CNS,
acting therapeutically within the nociceptive neuronal environment to
dampen an inﬂamed nociceptive nervous system.
One likely mechanism for the action of testosterone would involve
dampened pain signaling within the dorsal horn: In normal individuals
(Fig. 1A), a painful/stressful stimulus up-regulates Substance P which
has been found to stimulate the enzyme aromatase [58], which then
converts testosterone to estradiol within the CNS. Aromatase-positive
neurons associate with nociceptive estrogen receptor+ neurons that
are preproenkephalin mRNA+ [21,27,29,31], consistent with an up-
regulation of opiates, eventual down-regulation of Substance P [59]
and dampening of pain. In contrast, for ﬁbromyalgia patients (Fig. 1B),
their abnormally low testosterone levels, substantiated by others [26],
are proposed here to result in a “frustrated” cycle whereby a lack of tes-
tosterone substrate fails to stimulate the aromatase enzyme. Enzymatic
conversion of testosterone to estradiol by aromatase within the CNS is
therefore inadequate for induction of endogenous opiate-mediated
dampening of nociceptive signals, with the consequence that chronic,
diffuse and widespread “wind-up” pain ensues. Relating to this, ﬁbro-
myalgia patients' cerebrospinal ﬂuid was found to have lower levels of
the endogenous opioid peptide met-enkephalin-Arg6-Phe7 than that
of normal individuals [60] in one report, higher levels in another report
[61], and opioid receptors were changed as well [62]. The complex role
of opioid peptides and their receptors is emphasized by the demonstra-
tion that exogenous opioids given over the long term can become
hyperalgesic [14].
Other mechanisms proposed here by which testosterone is just as
likely to dampen nociception include anatomic locations in the CNS
other than the dorsal horn, for example at known centers of nociceptive
neuron modulation such as the midbrain androgen receptor-positive
PAG neurons that project to the on-cells and off-cells of the RVM, as
mentioned above. In this case, testosterone is likely to act on PAG neu-
rons to effect RVM on-cell/off-cell regulation and descending inhibition
of pain. Additional mechanisms likely involve the non-classical non-
genomic androgen receptor-mediated rapid actions known tomodulate
neuronal voltage- and ligand/neurotransmitter-gated ion-channels and
transporters at neuronal synapses or elsewhere, acting directly or indi-
rectly in a regulatory capacity [63]. For example, androgenic steroid ef-
fects on neuronal GABA-A receptors can be signiﬁcantly more potent
than benzodiazepines [63], which are used by some clinicians to treatﬁ-
bromyalgia. Finally, it would be logical that androgens act to coordinate
these nociceptive pathways as well as to coordinate between immuno-
logic, neuro-endocrine and reproductive systems in order to allow the
individual to navigate between response to threats from the environ-
ment (microbes and ﬁght-or-ﬂight), safety/survival, reproduction and
baseline function.
Considering these mechanisms together, abnormally low testoster-
one levels are likely to result in ampliﬁed ascending/descending facilita-
tion of nociception and reduced descending inhibitory control, resulting
in a widening pain ﬁeld and neuronal plasticity which can turn into
the entrenched chronic pain states found in ﬁbromyalgia patients. Pre-
existing testosterone deﬁciency states due to exhaustion (environmen-
tal stress) and/or genetic predisposition may also help explain why
some individuals are more susceptible to chronic pain than others.Treatment with testosterone is likely to beneﬁt these patients, and
that concept is supported by the preliminary study of White et al.Potential conﬂicts of interest
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